<DOC>
	<DOCNO>NCT01247285</DOCNO>
	<brief_summary>This study compare relative bioavailability ( rate extent absorption ) 90 mg Fluoxetine Hydrochloride Capsules Teva Pharmaceuticals , USA 90 mg PROZAC WEEKLYÂ® Capsules Eli Lilly Company follow single oral dose ( 1 x 90 mg ) healthy adult volunteer non-fasting condition .</brief_summary>
	<brief_title>90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>Screening Demographics : All volunteer select study healthy men woman 18 year age old time dose . The weight range exceed + 15 % height body frame per Desirable Weights Men 1983 Metropolitan Height Weight Table per Desirable Weights Women 1983 Metropolitan Height Weight Table . Screening Procedures : Each volunteer complete screening process within 28 day prior Period I dose . Consent document screen evaluation HIV antibody determination review , discuss , sign potential participant full implementation screening procedure . If female : Of childbearing potential , practice acceptable method birth control duration study judge investigator ( ) , Is postmenopausal least 1 year , Is surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) . Volunteers recent history drug alcohol addiction abuse . Volunteers presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurological system ( ) psychiatric disease ( determined clinical investigator ) . Volunteers whose clinical laboratory test value outside acceptable reference range confirm reexamination deem clinically significant . Volunteers demonstrate positive hepatitis B surface antigen screen reactive HIV antibody screen . Volunteers demonstrate positive drug abuse screen screen study . Female volunteer demonstrate positive pregnancy screen . Female volunteer currently breastfeed . Volunteers history allergic response ( ) fluoxetine relate drug . Volunteers history clinically significant allergy include drug allergy . Volunteers clinically significant illness 4 week prior Period I dose ( determined clinical investigator ) . Volunteers currently use tobacco product . Volunteers take drug know induce inhibit hepatic drug metabolism 30 day prior Period I dose . Volunteers report donate great 150 mL blood within 30 day prior Period I dose . All subject advise donate blood 4 week complete study . Volunteers donate plasma within 14 day prior Period I dose . All subject advise donate plasma 4 week complete study . Volunteers report receive investigational drug within 30 day prior Period I dose . Volunteers report take systemic prescription medication 14 day prior Period I dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>